This study aimed to investigate the mechanisms of Yu-Ping-Feng-San(YPFS) on attenuating allergic inflammation in the initial stage of atopic dermatitis(AD). AD mouse model was established with fluorescein isothiocyana...This study aimed to investigate the mechanisms of Yu-Ping-Feng-San(YPFS) on attenuating allergic inflammation in the initial stage of atopic dermatitis(AD). AD mouse model was established with fluorescein isothiocyanate(FITC) sensitization and elicitation. Epithelial barrier structure was observed with transmission electron microscope. The populations of dendritic cells(DCs)and group 2 innate lymphoid cells(ILC2 s) were detected by flow cytometry. Human immortalized keratinocyte(Ha Ca T) cells were stimulated with Poly(I:C)/TNF-α in vitro to assess thymic stromal lymphopoietin(TSLP), interleukin(IL)-33 and nuclear factor-κB(NF-κB) levels or expressions by immunofluorescence, enzyme linked immunosorbent assay(ELISA) and western blot. In the initial stage of AD, ear swelling and infiltration of inflammatory cells in ear tissues were markedly attenuated with YPFS treatments. The damaged structures of ear epithelium and the increased levels of Th2-cytokines induced by FITC were significantly rescued in YPFS-treated mice. The production of pro-allergic cytokines, TSLP and IL-33, as well as the cell populations of their target cells DCs and ILC2 s were decreased in AD model, respectively. Likewise, the levels of TSLP and IL-33 in Poly(I:C)/TNF-α-stimulated HaCaT cells showed the same results. Lower levels of p-NF-κB were detected with YPFS treatment, and the expressions of TSLP and IL-33 could be further decreased with inhibiting of NF-κB. Therefore, YPFS attenuates allergic inflammation in the initial stage of AD probably through regulating NF-κB-TSLP/IL-33 pathway, which may provide a novel effective target for the prevention and treatment of allergic diseases.展开更多
基金supported by the National Natural Science Foundation of China(Nos.81473395,81473390,and 81703733)the Priority Academic Program Development of Jiangsu Higher Education Institutions(PAPD)+1 种基金the Natural Science Foundation of Jiangsu Province(No.BK20141466)Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of China(No.JKLPSE201603)
文摘This study aimed to investigate the mechanisms of Yu-Ping-Feng-San(YPFS) on attenuating allergic inflammation in the initial stage of atopic dermatitis(AD). AD mouse model was established with fluorescein isothiocyanate(FITC) sensitization and elicitation. Epithelial barrier structure was observed with transmission electron microscope. The populations of dendritic cells(DCs)and group 2 innate lymphoid cells(ILC2 s) were detected by flow cytometry. Human immortalized keratinocyte(Ha Ca T) cells were stimulated with Poly(I:C)/TNF-α in vitro to assess thymic stromal lymphopoietin(TSLP), interleukin(IL)-33 and nuclear factor-κB(NF-κB) levels or expressions by immunofluorescence, enzyme linked immunosorbent assay(ELISA) and western blot. In the initial stage of AD, ear swelling and infiltration of inflammatory cells in ear tissues were markedly attenuated with YPFS treatments. The damaged structures of ear epithelium and the increased levels of Th2-cytokines induced by FITC were significantly rescued in YPFS-treated mice. The production of pro-allergic cytokines, TSLP and IL-33, as well as the cell populations of their target cells DCs and ILC2 s were decreased in AD model, respectively. Likewise, the levels of TSLP and IL-33 in Poly(I:C)/TNF-α-stimulated HaCaT cells showed the same results. Lower levels of p-NF-κB were detected with YPFS treatment, and the expressions of TSLP and IL-33 could be further decreased with inhibiting of NF-κB. Therefore, YPFS attenuates allergic inflammation in the initial stage of AD probably through regulating NF-κB-TSLP/IL-33 pathway, which may provide a novel effective target for the prevention and treatment of allergic diseases.
